Lunai Bioworks Inc. LNAI
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -44.97% | -66.36% | -59.43% | -54.53% | -19.96% |
| Depreciation & Amortization | -22.66% | -65.63% | -64.80% | 28.09% | 23.47% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -47.33% | -65.21% | -59.89% | -56.74% | -24.61% |
| Operating Income | 48.08% | 65.71% | 59.89% | 56.74% | 24.61% |
| Income Before Tax | 98.41% | -1,459.09% | 75.19% | 106.38% | -705.59% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 98.41% | -1,459.09% | 75.19% | 106.38% | -705.59% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 98.41% | -1,459.09% | 75.19% | 106.38% | -705.59% |
| EBIT | 48.08% | 65.71% | 59.89% | 56.74% | 24.61% |
| EBITDA | 48.01% | 65.80% | 59.86% | 57.22% | 24.77% |
| EPS Basic | 99.23% | -983.05% | 82.90% | 104.53% | -589.71% |
| Normalized Basic EPS | 77.19% | 76.79% | 71.34% | 68.83% | 48.56% |
| EPS Diluted | 99.23% | -991.66% | 82.90% | 104.53% | -584.58% |
| Normalized Diluted EPS | 77.19% | 76.56% | 71.34% | 68.83% | 48.56% |
| Average Basic Shares Outstanding | 106.24% | 53.97% | 45.11% | 40.76% | 16.80% |
| Average Diluted Shares Outstanding | 106.24% | 52.47% | 45.11% | 40.76% | 16.80% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |